Articles published by Leyden Laboratories B.V.

Leyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma Patients

Today 2:00 EDT

From Leyden Laboratories B.V.

Via Business Wire

Globally Recognized Impact Investors Back Leyden Labs’ Mission to Transform Protection Against Respiratory Viruses with €40 Million Investment

June 25, 2026

From Leyden Laboratories B.V.

Via Business Wire

Leyden Labs Demonstrates Feasibility of Novel Antibody-Based Nasal Spray for Flu Prevention

February 04, 2026

From Leyden Laboratories B.V.

Via Business Wire

Leyden Labs Secures €30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses

October 02, 2025

From Leyden Laboratories B.V.

Via Business Wire

Leyden Labs Lands €20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities

June 03, 2025

From Leyden Laboratories B.V.

Via Business Wire

Leyden Labs Publishes New Data Confirming Potential of Intranasal Antibody Approach

April 08, 2025

From Leyden Laboratories B.V.

Via Business Wire

Leyden Labs Raises $70M to Advance its Intranasal Antibody Programs to Protect against Influenza and other Viruses

January 09, 2025

From Leyden Laboratories B.V.

Via Business Wire

Leyden Labs Appoints Jintanat Ananworanich, M.D., Ph.D., as Chief Medical Officer

September 12, 2024

From Leyden Laboratories B.V.

Via Business Wire

Leyden Labs’ Intranasal PanFlu Antibody Enters the Clinic

April 19, 2023

From Leyden Laboratories B.V.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.